Midodrine to facilitate cardioprotective therapy in hypotensive HER2-positive breast cancer patients with cancer-therapy-related cardiac dysfunction-multicenter case experience
Cardiooncology. 2026 May 29. doi: 10.1186/s40959-026-00504-z. Online ahead of print.ABSTRACTBACKGROUND: HER2-targeted therapies significantly improve outcomes in HER2-positive breast cancer but are associated with cancer therapy-related cardiac dysfunction (CTRCD), which may necessitate interruption

